Patients with HER2+ breast cancer at risk for primary trastuzumab resistance could potentially be identified on the basis of a high-risk IL-6 promoter genotype, and future studies could be aimed at overcoming this resistance by inhibiting the IL-6 pathway. Here, ERBB2 is linked to breast carcinoma.